This project, initiated by the French National Cancer Institute, should make it possible to share data between nations and reduce inequalities in terms of patient care and research, according to France Inter. The United States, United Kingdom, Japan, Germany, Australia and Canada are also included.
Article written by
Published
Update
Reading time : 2 min.
![The National Cancer Institute (Inca), in Paris. (CHRISTOPHE SIMON / AFP)](https://www.francetvinfo.fr/pictures/vcHHy3VC4cYzx-LYDudJQlyzxsE/752x423/2023/05/10/645b4ab089bf9_institut-national-du-cancer.jpg)
The heads of the national cancer institutes of the seven most advanced countries in research have decided to unite and launched this Tuesday in Paris a “G7 of cancer”, reports France Inter on Wednesday May 10. At the initiative of the project, is the National Cancer Institute (Inca), within the framework of the ten-year French strategy for the fight against cancer. Around the Inca, and therefore France, join the United States, the United Kingdom, Japan, Germany, Australia and Canada.
>>> Health: beware of certain UV lamps in nail salons
These researchers decided to create this coordination group after the alarming observation made by the International Agency for Research on Cancer: in 2020, 19.3 million new cases of cancer and 10 million deaths were recorded worldwide. By 2040, it will be 20% more cases. This increase can be explained in particular by the growth and aging of the population. This G7 cancer has set four priorities for action: how to share data between these seven countries, reduce inequalities in cancer. The “G7 Cancer” also wants to accelerate prevention and boost research.
Research is progressing too slowly
For the next two years, the group presidency will be provided by France and the National Cancer Institute, reports France Inter. According to Thierry Breton, general manager of the Inca, certain forms of cancer still remain unanswered today and on the scale of a single country, research is progressing too slowly. “On cancers with poor prognoses, we must strengthen research on pancreatic cancers, for example, he argues. It can also be for diseases where there are few cases: how we organize international access to clinical trials. This is very important, because it allows more patients tomorrow to have access to clinical trials, and therefore to have therapeutic solutions. But this also allows us to have a study framework that is broader, which allows us to have more scientifically relevant conclusions, more statistically robust”advances the specialist.
Tea #G7Cancer meeting has started at the French National Cancer Institute #INCa @Institute_cancer pic.twitter.com/K8X46JSrjw
– National Cancer Institute (@Institut_cancer) May 9, 2023
A collaboration also deemed essential by Dr. Catherine Elliott, Director of the UK Cancer Research Center: “We have recently observed that colorectal cancer is increasing in young populations. And that is something that we have difficulty understanding. On issues as concrete as these, we all need to work together. research knows no borders. So if we work together, if we collaborate, we can really accelerate progress”.
This G7 cancer primarily targets four diseases, where the prognosis is still very poor: cancer of the pancreas, liver, stomach and esophagus.